Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer

British Journal of Cancer

Volumn 77, Issue 6, 1998, Pages 932-940

  Knoop, A ^a   Andreasen, P A ^b   Andersen, J A ^a   Hansen, S ^a   Laenkholm A V ^a   Simonsen, A C W ^b   Andersen, J ^b   Overgaard, J ^b   Rose, C ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Breast neoplasm mortality; PAI 1; Plasminogen; Prognosis; Urokinase

Indexed keywords

ESTROGEN RECEPTOR; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; STEROID RECEPTOR; UROKINASE;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TISSUE LEVEL; TUMOR VOLUME;

EID: 0031952403     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.154     Document Type: Article

References (45)

1. Albert SR, Ingle JN, Roche PR, Cha SS, Wold LE, Farr GH Jr. Krook JE and Wieand HS (1996) Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. cancer 78: 764-772
2. Andersen KW, Mouridsen HT, Casiberg T, Fischerman K, Andersen J, Hou-Jensen K, Brincker H, Johansen H, Henriksen E, Roth M and Rossing N (1981) Organization of the Danish adjuvant trials in breast cancer. Danish Med Bull 28: 102-106
3. Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, Rasmussen BB and Poulsen HS (1990) The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 26: 442-449
4. Andreasen PA, Nielsen LS, Kristensen P, Grøndahl-Hansen J, Skriver L, and Dano K (1986) Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator but not its proenzyme. J Biol Chem 261: 7644-7657
5. Andreasen PA, Georg B, Lund LR, Riccio A and Stacey SN (1990) Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68: 1-19
6. Andreasen PA, Kjoller L, Christensen L and Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis, A review. Int J Cancer 71: 1-22
7. Bianchi E, Cohen RL, Thor AT, Todd RF 3rd, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA and Smith HS (1994) The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54: 861-866
8. Bloom HJC and Richardson WW (1957) Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377
9. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A and Oglobine J (1994) Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405
10. Christensen L, Simonsen ACW, Heegaard CW, Moestrup SK, Andersen JA and Andreasen PA (1996) Immunohistochemical localization of urokinase-type plasminogen activator in human breast carcinomas. Int J Cancer 66: 441-452
11. Danø K, Andreasen PA, Crøndahl-Hansen J. Kristensen P, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266
12. De Mascarel I, Soubeyran I, MacGrogan G, Wafflart J, Bonichon F, Durand M, Avril A, Mauriac L, Trojani M and Coindre JM (1997) Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas. Concordance with biochemical assay and prognostic significance. Appl Immunohistochem 3: 222-231
13. Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618
14. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HJ (1988) Urokinase plasminogen activator. a marker for aggressive breast carcinomas. Preliminary report. Cancer 62: 531-533
15. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ and Andreasen P (1990) Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829
16. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ and Andreasen PA (1994) Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 74: 2276-2280
17. Dvorak HF, Brown LF, Detmar M and Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 146: 1029-1039
18. EORTC Breast Cancer Co-operative Group (1980) Revision of the standards for assessment of hormone receptors in human breast cancer. Eur J Cancer 16: 1513-1515
19. Esteban JM, Ahn C, Baltifora H and Felder B (1994) Quantitative immunohistochemical assay for hormonal receptors; technical aspects and biological significance. J Cell Biochem Suppl 19: 138-145
20. Fernö M, Bendahl PO, Borg A, Brundell J, Hirschberg L, Olsson H and Killander D (1996) Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a Iuminometric immunoassay. Eur J Cancer 32A: 793-801
21. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F and Klijn JG (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105
22. Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F and Klijn JG (1994a) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658
23. Foekens JA, Schmitt M, Peters HA, Look MP, van Putten WL, Kramer MD, Jänicke F and Klijn JG (1994b) Association of PAI-1 with metastasis-free survival in breast cancer: comparison with HR, PgR, PS2, cathepsin D and uPA. In Prospectives in Diagnosis and Treatment of Breast Cancer. Schmidt M (ed). pp. 197-205. Excerpta Medica: Amsterdam
24. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med 1: 27-31
25. Foucré D, Bouchet C, Hacene K, Pourreau Schneider N, Gentile A, Martin PM, Desplaces A and Oglobine J (1991) Relationship between cathepsin D. urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer 64: 926-932
26. Göhring UJ, Scharl A, Thelen U, Ahr A and Titius BR (1995) Prognostic value of immunohistochemical determination of urokinase plasminogen activator in primary breast cancer. pathologe 14: 398-403
27. Grebenschikov N, Geurts-Moespot A, De Witte H, Heuvel J, Leake R, Sweep F and Benraad T (1997) A sensitive and robust assay for urokinase and tissue type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Boil Markers 12: 6-14
28. Grøndahl-Hansen J, Ralfkiaer E, Nielsen LS, Kristensen P, Frentz G and Danø K (1987) Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. J Invest Dermatol 88: 28-32
29. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K and Blichert Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
30. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Ulm K, Grossner W and Graeff H (1990) Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
31. Jänicke F, Schmitt M and Graeff H (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 17: 303-312
32. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195 208
33. Liotta LA, Steeg PS and Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336
34. Mignatti P and Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195
35. Munch M, Heegaard C, Jensen PH and Andreasen PA (1991) Type-1 inhibitor of plasminogen activators. Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies. FEBS Lett 295: 102-106
36. Munch M, Heegaard CW and Andreasen PA (1993) Interconversions between active. inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1202: 29-37
37. Nielsen LS, Andreasen PA, Grondahl-Hansen J, Huang JY, Kristensen P and Danø K (1986a) Monoclonal antibodies to human 54 000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells - inhibitor neutralization and one-step affinity purification. Thromb Haemost 55: 206 212
38. Nielsen LS, Grøndahl-Hunsen J, Andreasen PA, Skriver L, Zeuthen J and Danø K (1986b) Enzyme-linked immunosorbent assay for human urukinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. J Immunoassay 7: 209-228
39. Nykjær A, Petersen CM, Møller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thogersen HC, Munch M and Andreasen PA (1992) Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. Evidence tha the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 267: 14543-14546
40. Pfeiffer P, Grabau DA, Nielsen O and Clausen PP (1996) Immunohistochemical bulk staining of slides using a rack peroxidase-labelled streptavidin-biotin technique. Appl Immunohistochem 4: 135-138
41. Ploug M, Kjalke M, Rønne H, Weidle U, Hoyer Hansen G and Danø K (1993) Localizalion of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J Biol Chem 268: 17539-17546
42. Pöllänen J, Saksela O, Salonen EM, Andreasen P, Nielsen L, Danø K and Vaheri A (1987) Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 104: 1085-1096
43. Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero Pous M, Deytieux S, Le Doussal V, Tubiana Hulin M and Brunet M (1992) Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266-1272
44. Stephens RW, Bokman AM, Myohanen HT, Reisberg T, Tapiovaara H, Pedersen N, Grøndahl Hansen J, Llinas M and Vaheri A (1992) Heparin binding to the urokinase kringle domain, Biochemistry 31: 7572-7579
45. Thorpe SM (1987) Steroid receptors in breast cancer: sources of interlaboratory variation in dextran-charcoal assays. Breast Cancer Res Treat 11: 175-189